Hoffmann-la Roche

This study tested two immunotherapy drugs (tiragolumab and atezolizumab) given before and after surgery, with or without chemotherapy, for people with early-stage non-small cell lung cancer. The goal was to see if the treatment was safe and could shrink tumors enough to make surg…

This phase 3 study tested whether adding atezolizumab (an immunotherapy) to cabozantinib (a targeted therapy) works better than cabozantinib alone for people with advanced kidney cancer that has grown after prior immunotherapy. The trial enrolled 522 adults with inoperable or met…

This study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results ar…

This study tested several immunotherapy-based drug combinations in people with advanced non-small cell lung cancer. It included two groups: those who had not yet received treatment and those whose cancer had worsened after standard therapies. The goal was to see if these combinat…

This phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…